The takeaway
Rapport Therapeutics, Inc. Common Stock shows a pronounced seasonal pattern over 2 years of data — strongest in September (+41.3%) and softest in February (−39.6%).
Right now
In July, the stock has risen 50% of years, averaging +8.1%, about +6.0 pts better than the S&P 500.
The full picture
Rapport Therapeutics, Inc. Common Stock's most dependable month has been September, higher in 2 of 2 years; February has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in September (+41.4 pts); it has trailed the market most in February (−39.3 pts).
“vs S&P” is Rapport Therapeutics, Inc. Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating Rapport Therapeutics, Inc. Common Stock’s own seasonal edge from broad market drift.
Reality check
Not enough recent September history to say whether the pattern still holds.
Figures are the typical (median) September return and how often it rose — the last 2 years versus the last 2(the heatmap’s default window). This verdict stays anchored to that 2-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: September, up in all 2 Septembers while the other eleven tend to blur together.
Its average (+41.3%) and median (+41.3%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even September ranges by 40.1% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: September has cleared the S&P 500 by +41.4 points above the index. It bucks the broad tape, besides: September lifts just 39% of stocks across the market.
The strength clusters rather than stands alone — August–October forms a firm stretch that carries much of the year. On the other side of the ledger, February has been the soft spot — the weakest of 4 months that average a loss (−39.6%), and the edge isn't year-round — the stock has trailed the S&P 500 in February, May, and December. Its roughest month on record was a −39.6% February in 2025 — a reminder of how hard even a seasonal name can fall.
The takeaway is less about when to buy than what to expect: September aside, the stock's months offer little reliable tilt. With a short 2-year record, the signal is best held loosely.
Short answers on the stock's best month (September), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2024 its best month (September, +41.3%) has run well ahead of its worst (February, −39.6%) — the heatmap above shows how steady that gap has been year to year.
September has been the strongest, averaging +41.3% and closing higher in all 2 years on record since 2024.
It's the weakest, averaging −39.6% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade